Pharmafile Logo

Glaucoma in perspective

- PMLiVE

Merck’s investigational pneumococcal vaccine shows promise in older adults

V116 is designed to address the strains that represent adult pneumococcal disease

How to Increase Engagement During Virtual Events

Tip #4 - How do you plan the agenda for your virtual event?We suggest to invite participant input to build and personalize the engagement.Invite participant input and rethink your agenda...

Impetus Digital

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

- PMLiVE

New research highlights mental health support gap for autoimmune disease patients

More than 1,800 patients with SARDs were surveyed for neurological and psychiatric symptoms

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

- PMLiVE

Moderna and Merck’s skin cancer vaccine enters late-stage development

More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

- PMLiVE

Astellas and PeptiDream announce protein degrader research collaboration

Protein degrader drugs have been proposed as a way to address ‘undruggable’ targets

EU flag

EMA reports actions to improve EU clinical trials conducted during health emergencies

All proposed actions will be acknowledged by the European Commission, EMA and member states

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

- PMLiVE

Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

Evrysdi is already approved in the EU to treat SMA patients aged two months or older

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links